Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
Päätekijät: | , , , , , , , , , , , , , , |
---|---|
Aineistotyyppi: | Conference item |
Julkaistu: |
American Society of Hematology
2016
|